Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5845643 | Pulmonary Pharmacology & Therapeutics | 2015 | 35 Pages |
Abstract
Initial data demonstrated that the NFAT pathway is increased in stimulated lymphocytes from asthmatics. To confirm a role for the channel we showed that a selective inhibitor, Synta 66, blocked mediator production from lymphocytes. Synta 66 inhibited CD2/3/28 induced IL-2, IL-7, IL-13 & IFNÎ¥ in a concentration-dependent manner in healthy and severe asthma donors, with over 60% inhibition observed for all cytokines. NFAT pathway was also increased in a pre-clinical asthma model. In this model we have demonstrated that CRAC played a central role in the airway inflammation and late asthmatic response (LAR). In conclusion, our data provides evidence that suggests targeting CRAC channels could be of therapeutic benefit for asthma sufferers.
Keywords
SOCEItk inhibitorHNST helperLCKITKCRACICSACQBALDEXNFATAsthmaMild asthmaSevere asthmaenzyme linked immunosorbent assayinterleukinELISAForced expiratory volumeDexamethasoneStore operated calcium entryFevbronchoalveolar lavageLymphocytesAsthma Control QuestionnaireCRAC channelInhaled corticosteroidsglucocorticoid receptor
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Manminder Kaur, Mark A. Birrell, Bilel Dekkak, Sophie Reynolds, Sissie Wong, Jorge De Alba, Kristof Raemdonck, Simon Hall, Karen Simpson, Malcolm Begg, Maria G. Belvisi, Dave Singh,